Please assess the completion status of the following clinical trial:

Trial Title: Antiepileptic Drugs and Vascular Risk Markers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Acute subarachnoid hemorrhage, Hunt-Hess Grades I-IV~* Within 48 hours of admission~Exclusion Criteria:~* Grade V subarachnoid hemorrhage~* Being treated with a lipid-lowering agent~* Contraindication to phenytoin, valproate, or levetiracetam (e.g. history of allergy to one of these agents)~* Contraindication to receiving no antiepileptic drug treatment (e.g. history of pre-existing epilepsy, seizure activity on admission EEG)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
- 2 (Type: ACTIVE_COMPARATOR): Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
- 3 (Type: ACTIVE_COMPARATOR): Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
- 4 (Type: NO_INTERVENTION): Participants randomized to Group 4 will receive no drug intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).